Diplomat Pharmacy extends specialty reach with BioRx acquisition

CINCINNATI — Diplomat Pharmacy on Thursday announced the acquisition of the specialty pharmacy BioRx. Details of the transaction, which is expected to close in March, were not provided. 

 

“Since we started BioRx in 2004, our goal has been to build the country’s most patient-centered specialty pharmacy that focuses on chronic and complex therapies," stated Phil Rielly, BioRx cofounder. "Diplomat shares this focus and represents the right partner, at the right time, for us to continue our mission into the future.

 

“We are very excited to expand Diplomat’s infusion services with the acquisition of BioRx. The combined resources of both companies will make us much stronger and unique within the infusion services industry,” commented Phil Hagerman, Diplomat chairman and CEO. “The specialty pharmacy market has evolved substantially over the last decade and this partnership will help Diplomat be even more prepared to grow and thrive in the years to come.”

 

Both BioRx cofounders, Rielly and Eric Hill, have made multiyear commitments to help lead the combined organization going forward. “With the collective resources of BioRx and Diplomat, we become a stronger company and achieve a more competitive position in the market,” said Hill. “Together, we offer a robust portfolio of specialty products across an integrated national pharmacy network — all while maintaining a delivery model that customizes care at the individual level. That’s good for patients, prescribers, payers and drug manufacturers.”